1. Home
  2. MUX vs RAPP Comparison

MUX vs RAPP Comparison

Compare MUX & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$21.84

Market Cap

1.6B

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$39.64

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUX
RAPP
Founded
1979
2022
Country
Canada
United States
Employees
1432
N/A
Industry
Precious Metals
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
MUX
RAPP
Price
$21.84
$39.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$26.63
$48.50
AVG Volume (30 Days)
1.0M
290.1K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$37.86
N/A
Revenue Next Year
$31.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.25
$8.20
52 Week High
$29.70
$42.27

Technical Indicators

Market Signals
Indicator
MUX
RAPP
Relative Strength Index (RSI) 46.83 61.52
Support Level $20.43 $25.48
Resistance Level $26.30 $41.33
Average True Range (ATR) 1.25 2.08
MACD -0.17 0.18
Stochastic Oscillator 23.39 84.38

Price Performance

Historical Comparison
MUX
RAPP

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: